BRPI0515528A - n-metil hidroxietilamina úteis no tratamento de condições do sistema nervoso central - Google Patents
n-metil hidroxietilamina úteis no tratamento de condições do sistema nervoso centralInfo
- Publication number
- BRPI0515528A BRPI0515528A BRPI0515528-2A BRPI0515528A BRPI0515528A BR PI0515528 A BRPI0515528 A BR PI0515528A BR PI0515528 A BRPI0515528 A BR PI0515528A BR PI0515528 A BRPI0515528 A BR PI0515528A
- Authority
- BR
- Brazil
- Prior art keywords
- hydroxyethylamine
- methyl
- useful
- nervous system
- central nervous
- Prior art date
Links
- OPKOKAMJFNKNAS-UHFFFAOYSA-N N-methylethanolamine Chemical compound CNCCO OPKOKAMJFNKNAS-UHFFFAOYSA-N 0.000 title abstract 3
- 210000003169 central nervous system Anatomy 0.000 title abstract 3
- 208000024827 Alzheimer disease Diseases 0.000 abstract 1
- 230000000626 neurodegenerative effect Effects 0.000 abstract 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C233/00—Carboxylic acid amides
- C07C233/64—Carboxylic acid amides having carbon atoms of carboxamide groups bound to carbon atoms of six-membered aromatic rings
- C07C233/77—Carboxylic acid amides having carbon atoms of carboxamide groups bound to carbon atoms of six-membered aromatic rings having the nitrogen atom of at least one of the carboxamide groups bound to a carbon atom of a hydrocarbon radical substituted by amino groups
- C07C233/78—Carboxylic acid amides having carbon atoms of carboxamide groups bound to carbon atoms of six-membered aromatic rings having the nitrogen atom of at least one of the carboxamide groups bound to a carbon atom of a hydrocarbon radical substituted by amino groups with the substituted hydrocarbon radical bound to the nitrogen atom of the carboxamide group by an acyclic carbon atom
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D209/00—Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom
- C07D209/02—Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom condensed with one carbocyclic ring
- C07D209/04—Indoles; Hydrogenated indoles
- C07D209/10—Indoles; Hydrogenated indoles with substituted hydrocarbon radicals attached to carbon atoms of the hetero ring
- C07D209/12—Radicals substituted by oxygen atoms
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D213/00—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members
- C07D213/02—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members
- C07D213/04—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom
- C07D213/60—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
- C07D213/78—Carbon atoms having three bonds to hetero atoms, with at the most one bond to halogen, e.g. ester or nitrile radicals
- C07D213/81—Amides; Imides
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D263/00—Heterocyclic compounds containing 1,3-oxazole or hydrogenated 1,3-oxazole rings
- C07D263/02—Heterocyclic compounds containing 1,3-oxazole or hydrogenated 1,3-oxazole rings not condensed with other rings
- C07D263/30—Heterocyclic compounds containing 1,3-oxazole or hydrogenated 1,3-oxazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members
- C07D263/34—Heterocyclic compounds containing 1,3-oxazole or hydrogenated 1,3-oxazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
Landscapes
- Organic Chemistry (AREA)
- Chemical & Material Sciences (AREA)
- Health & Medical Sciences (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- General Health & Medical Sciences (AREA)
- Neurology (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Biomedical Technology (AREA)
- Medicinal Chemistry (AREA)
- Neurosurgery (AREA)
- Hospice & Palliative Care (AREA)
- Psychiatry (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
- Pyridine Compounds (AREA)
- Heterocyclic Carbon Compounds Containing A Hetero Ring Having Nitrogen And Oxygen As The Only Ring Hetero Atoms (AREA)
- Indole Compounds (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US61177704P | 2004-09-21 | 2004-09-21 | |
| PCT/IB2005/002877 WO2006032999A1 (en) | 2004-09-21 | 2005-09-09 | N-methyl hydroxyethylamine useful in treating cns conditions |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| BRPI0515528A true BRPI0515528A (pt) | 2008-07-29 |
Family
ID=35559297
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| BRPI0515528-2A BRPI0515528A (pt) | 2004-09-21 | 2005-09-09 | n-metil hidroxietilamina úteis no tratamento de condições do sistema nervoso central |
Country Status (7)
| Country | Link |
|---|---|
| US (1) | US20080132552A1 (enExample) |
| EP (1) | EP1794114A1 (enExample) |
| JP (1) | JP2008513432A (enExample) |
| BR (1) | BRPI0515528A (enExample) |
| CA (1) | CA2581023A1 (enExample) |
| MX (1) | MX2007002459A (enExample) |
| WO (1) | WO2006032999A1 (enExample) |
Families Citing this family (24)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EP2307345A4 (en) * | 2008-07-01 | 2012-05-02 | Purdue Research Foundation | NON-PEPTIDINHIBITORS OF HIV-1 PROTEASE |
| WO2011133224A1 (en) | 2010-04-22 | 2011-10-27 | Intra-Cellular Therapies, Inc. | Organic compounds |
| CN102344402B (zh) * | 2010-07-30 | 2015-01-07 | 中国人民解放军军事医学科学院毒物药物研究所 | 苯并氮杂环羟乙基胺类化合物、其制备方法和用途 |
| US20150080404A1 (en) | 2012-04-14 | 2015-03-19 | Intra-Cellular Therapies, Inc. | Novel compositions and methods |
| PL2968320T3 (pl) | 2013-03-15 | 2021-05-17 | Intra-Cellular Therapies, Inc. | Związki organiczne |
| US9956227B2 (en) | 2013-12-03 | 2018-05-01 | Intra-Cellular Therapies, Inc. | Method for the treatment of residual symptoms of schizophrenia |
| AU2015240526A1 (en) | 2014-04-04 | 2016-11-24 | Intra-Cellular Therapies, Inc. | Organic compounds |
| JP2017509686A (ja) | 2014-04-04 | 2017-04-06 | イントラ−セルラー・セラピーズ・インコーポレイテッドＩｎｔｒａ−Ｃｅｌｌｕｌａｒ Ｔｈｅｒａｐｉｅｓ， Ｉｎｃ． | 有機化合物 |
| CN113786407B (zh) | 2016-01-26 | 2024-05-24 | 细胞内治疗公司 | 有机化合物 |
| EP3407889B1 (en) | 2016-03-25 | 2021-05-19 | Intra-Cellular Therapies, Inc. | Organic compounds and their use in treating or preventing central nervous system disorders |
| JP2019510039A (ja) | 2016-03-28 | 2019-04-11 | イントラ−セルラー・セラピーズ・インコーポレイテッドＩｎｔｒａ−Ｃｅｌｌｕｌａｒ Ｔｈｅｒａｐｉｅｓ， Ｉｎｃ． | 新規組成物および方法 |
| EP3525763B1 (en) | 2016-10-12 | 2025-03-05 | Intra-Cellular Therapies, Inc. | Amorphous solid dispersions |
| JP6987868B2 (ja) | 2016-12-29 | 2022-01-05 | イントラ−セルラー・セラピーズ・インコーポレイテッドIntra−Cellular Therapies, Inc. | 有機化合物 |
| WO2018126140A1 (en) | 2016-12-29 | 2018-07-05 | Intra-Cellular Therapies, Inc. | Organic compounds |
| MX395214B (es) | 2017-03-24 | 2025-03-25 | Intra Cellular Therapies Inc | Composiciones novedosas y metodos |
| EP3658145A4 (en) | 2017-07-26 | 2021-04-21 | Intra-Cellular Therapies, Inc. | ORGANIC COMPOUNDS |
| US11427587B2 (en) | 2017-07-26 | 2022-08-30 | Intra-Cellular Therapies, Inc. | Organic compounds |
| WO2019183341A1 (en) | 2018-03-23 | 2019-09-26 | Intra-Cellular Therapies, Inc. | Organic compounds |
| EP3801527B1 (en) | 2018-06-08 | 2025-02-19 | Intra-Cellular Therapies, Inc. | Fused gamma-carbolines for acute treatment of anxiety or depression |
| US12144808B2 (en) | 2018-08-29 | 2024-11-19 | Intra-Cellular Therapies, Inc. | Compositions and methods |
| EP3843738A4 (en) | 2018-08-31 | 2022-06-01 | Intra-Cellular Therapies, Inc. | NEW METHODS |
| US10695345B2 (en) | 2018-08-31 | 2020-06-30 | Intra-Cellular Therapies, Inc. | Pharmaceutical capsule compositions comprising lumateperone mono-tosylate |
| CN114072150A (zh) | 2019-07-07 | 2022-02-18 | 细胞内治疗公司 | 新方法 |
| US12414948B2 (en) | 2022-05-18 | 2025-09-16 | Intra-Cellular Therapies, Inc. | Methods |
Family Cites Families (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN1217920C (zh) | 2000-06-30 | 2005-09-07 | 艾兰制药公司 | 治疗早老性痴呆的化合物 |
| AP2004002952A0 (en) | 2001-07-11 | 2004-03-31 | Elan Pharm Inc | N-(3-amino-2-hydroxy-propyl) substituted alkylamide compounds. |
| GB0228410D0 (en) | 2002-12-05 | 2003-01-08 | Glaxo Group Ltd | Novel Compounds |
-
2005
- 2005-09-09 MX MX2007002459A patent/MX2007002459A/es unknown
- 2005-09-09 EP EP05783711A patent/EP1794114A1/en not_active Withdrawn
- 2005-09-09 WO PCT/IB2005/002877 patent/WO2006032999A1/en not_active Ceased
- 2005-09-09 JP JP2007531865A patent/JP2008513432A/ja not_active Withdrawn
- 2005-09-09 BR BRPI0515528-2A patent/BRPI0515528A/pt not_active IP Right Cessation
- 2005-09-09 CA CA002581023A patent/CA2581023A1/en not_active Abandoned
- 2005-09-21 US US11/231,483 patent/US20080132552A1/en not_active Abandoned
Also Published As
| Publication number | Publication date |
|---|---|
| WO2006032999A1 (en) | 2006-03-30 |
| CA2581023A1 (en) | 2006-03-30 |
| MX2007002459A (es) | 2007-05-04 |
| EP1794114A1 (en) | 2007-06-13 |
| US20080132552A1 (en) | 2008-06-05 |
| JP2008513432A (ja) | 2008-05-01 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| BRPI0515528A (pt) | n-metil hidroxietilamina úteis no tratamento de condições do sistema nervoso central | |
| DE602004020072D1 (de) | 1,2,3,4-tetrasubstituiertes indol zur behandlung von atemwegserkrankungen | |
| UY28011A1 (es) | Compuestos de tiazol para el tratamiento de trastornos neurodegenerativos | |
| ATE409176T1 (de) | 1-phenylalkancarbonsäurederivate zur behandlung neurodegenerativer erkrankungen | |
| DE602005009748D1 (de) | 3-phenyl-pyrazol-derivate als modulatoren des zur behandlung damit zusammenhängender störungen nützlichen 5-ht-2a-serotonin-rezeptors | |
| ATE550338T1 (de) | Spiropiperidininhibitoren von beta-secretase zur behandlung von alzheimer-krankheit | |
| ZA200709535B (en) | Methods and compositions for the treatment of CNS-related conditions | |
| TW200800976A (en) | New compounds for the treatment of neurological, psychiatric or pain disorders | |
| ATE440099T1 (de) | Herstellung und anwendung von tetrahydropyrrolo ä3, 2-cüpyridin-4-onderivaten zur behandlung von obesitas und psychiatrischen und neurologischen erkrankungen | |
| SG157231A1 (en) | Substituted p-diaminobenzene derivatives | |
| EA200601074A1 (ru) | Применение производных пептидов для лечения болей, связанных с заболеванием центральной нервной системы (центральной невропатической боли) | |
| DE60312736D1 (de) | 1,2,4-triaminobenzolderivate zur behandlung von erkrankungen des zentralnervensystems | |
| DE602004003952D1 (de) | Substituierte tetrahydrobenzothienopyrimidinamine verbindungen geeignet zur behandlung von hyper-proliferative disorders | |
| ATE422498T1 (de) | Tetrahydro-pyrazinoä1,2-aüindole für die behandlung von krankheiten des zentralnervensystems | |
| ATE478863T1 (de) | Heterotetracyclische verbindungen als tpo- mimetica | |
| DE60304695D1 (de) | 7-ARYLSULFONAMID-2,3,4,5-TETRAHYDRO-1H-BENZOiDöAZEPINE MIT 5-HT6 REZEPTOR AFFINITÄT ZUR BEHANDLUNG VON ZENTRALNERVENSYSTEMERKRANKUNGEN | |
| ATE529427T1 (de) | Ä1h-indol-5-yl)-heteroaryloxyü-(1-aza-bicyclo- ä3.3.1ü-nonane als cholinergische liganden des n- achr zur behandlung psychotischer und neurodegenerativer leiden | |
| IL205045A0 (en) | Piperidinyl and piperazinyl modulators of ?? - secretase | |
| MX2010000956A (es) | Derivados de isoftalamida que inhiben actividad de beta-secretasa. | |
| NZ606276A (en) | Fastening Means | |
| BR0306855A (pt) | Método para o tratamento de distúrbios cognitivos | |
| ATE552251T1 (de) | Thiophen- und furanverbindungen | |
| NO20055563L (no) | Midler for behandlingen av lavere abdominale lidelser | |
| EA200601607A1 (ru) | Сульфонамидные соединения для лечения нейродегенеративных расстройств | |
| ATE410166T1 (de) | 4-phenyl-5-oxo-1,4,5,6,7,8-hexahydrochinolin- derivate zur behandlung von unfruchtbarkeit |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| B08F | Application dismissed because of non-payment of annual fees [chapter 8.6 patent gazette] |
Free format text: REFERENTE AS 5A E 6A ANUIDADES. |
|
| B08K | Patent lapsed as no evidence of payment of the annual fee has been furnished to inpi [chapter 8.11 patent gazette] |
Free format text: REFERENTE AO DESPACHO 8.6 PUBLICADO NA RPI 2160 DE 29/05/2012. |